BPC-157
Body Protection Compound. Pentadecapeptide. GI mucosal repair. Post-surgical orthopedic recovery.
Weight
1,419 Da
Half-life
Under 30 minutes
Chain
15 amino acids
Studies
20 referenced. Latest 2024.
Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library. Request access.
Overview
BPC-157 is a 15-amino acid partial sequence derived from a protein found in gastric juice. It is the most studied regenerative peptide in tissue repair. Rodent, rabbit, and non-companion-animal veterinary data across gut, tendon, ligament, muscle, and nervous tissue.
Broad spectrum. Cross species. Well characterized safety in preclinical work.
Mechanism of action
- 01Modulates nitric oxide system for vascular and tissue repair.
- 02Upregulates VEGF and growth hormone receptor expression in injured tissue.
- 03Accelerates fibroblast migration into wound sites.
- 04Drives angiogenesis and capillary formation.
- 05Protects gastric and intestinal mucosa from ulcerogenic insults.
Molecular data
| Property | Value |
|---|---|
| Molecular weight | 1,419 Da |
| Chain length | 15 amino acids |
| Type | Gastric juice partial sequence |
| Route | Subcutaneous injection. Oral bioavailability preserved. |
Species applicability
Dog
Preclinical extrapolation. Post-surgical tendon and ligament healing. Chronic partial tears in performance and working dogs. Inflammatory bowel disease refractory to conventional therapy.
Cat
Chronic enteropathy adjunct. Post-surgical recovery. Feline IBD support in cases refractory to steroids.
Horse
Growing use in equine sports medicine for tendon and ligament injury.
Prescribing indications
Post-surgical tendon and ligament healing.
IBD refractory to conventional therapy.
Slow-to-heal wounds.
Neuropathy and nerve injury adjunct.
Dosing framework
Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library.
Request accessReconstitution and administration
Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library.
Request accessInteractions
What to expect
Safety profile
Wide therapeutic window in rodent studies. No documented lethal dose. No mutagenicity or teratogenicity reported. Cancer contraindication urged in patients with active malignancy given uncertain effects on tumor angiogenesis.
Research library
Related peptides
Regulatory footing
This monograph describes a compounded veterinary medication available by prescription only through a licensed veterinarian inside an active veterinarian-client-patient relationship. Not FDA-approved for animal or human use. Compounded on a patient-specific basis under FDA Guidance for Industry #256. For educational use by licensed veterinarians. Not intended for consumer self-prescribing.
For licensed veterinarians only. Compounded under FDA GFI 256. Not FDA-approved.